

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claim 1. (Currently Amended) A pharmaceutical composition comprising an effective amount of loteprednol or a pharmaceutically acceptable ~~tolerable~~ ester thereof and azelastine ~~at least one antihistamine~~.

Claim 2. (Currently Amended) The composition according to claim 1, wherein the azelastine ~~antihistamine~~ is administrable nasally or ocularly.

Claim 3. (Canceled)

Claim 4. (Previously Presented) The composition according to claim 1, wherein the pharmaceutically tolerable ester is loteprednol etabonate.

Claim 5. (Currently Amended) A method for the treatment of one or more allergic disorders selected from the group consisting of allergic rhinitis and allergic conjunctivitis ~~allergic disorders of the lower or upper airways and the eyes~~, comprising administering to a person in need thereof, an effective amount of loteprednol or a pharmaceutically acceptable ester thereof and ~~at least one~~ intranasally or intraocularly administrable azelastine ~~antihistamine~~, optionally

together with customary excipients or vehicles, for simultaneous, sequential or separate administration.

Claim 6. (Canceled)

Claim 7. (Currently Amended) The method according to claim 9 ~~5~~, wherein the loteprednol ~~substance~~ is administered as an inhalable liquid preparation.

Claim 8. (Currently Amended) The method according to claim 9 ~~5~~, wherein the azelastine ~~which~~ is administered orally.

Claim 9. (Currently Amended) A method for the treatment and prophylaxis of one or more allergic disorders selected from the group consisting of allergic rhinitis and allergic conjunctivitis ~~allergic airway and eye disorders~~, comprising administering to a person in need thereof, an effective amount of loteprednol and azelastine ~~at least one intranasally or intraocularly administrable antihistamine~~, wherein the loteprednol or a pharmaceutically acceptable ester thereof and the azelastine ~~is antihistamine(s)~~ are administered simultaneously, sequentially or separately, optionally together with customary excipients or vehicles.

Claim 10. (Canceled)

Claim 11. (Currently Amended) A method for the treatment of one or more allergic disorders selected from the group consisting of allergic rhinitis and allergic

conjunctivitis allergic rhinitis or rhinoconjunctivitis comprising administering to a patient in need thereof, a combination of loteprednol or a pharmaceutically acceptable ester thereof and azelastine ~~an antihistamine~~ for simultaneous, sequential or separate administration.

Claim 12 (New) The composition according to claim 1, wherein the daily dose of loteprednol is between 10 and 500  $\mu\text{g}$  and the daily does of azelastine is between 50 and 500  $\mu\text{g}$ .

Claim 13. (New) The method according to any one of claims 5, 7 or 11, wherein the daily dose of loteprednol is between 10 and 500  $\mu\text{g}$ , and the daily dose of azelastine is between 50 and 500  $\mu\text{g}$ .

Claim 14. (New) The method of claim 12, wherein the daily dose of loteprednol is between 50 and 200  $\mu\text{g}$  and the daily does of azelastine is between 100 and 200  $\mu\text{g}$ .

Claim 15. (New) The method of claim 13, wherein the daily dose of loteprednol is between 50 and 200  $\mu\text{g}$  and the daily does of azelastine is between 100 and 200  $\mu\text{g}$ .